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Abstract
Background:  The human neural stem cell line CTX0E03 was developed for the cell based
treatment of chronic stroke disability. Derived from fetal cortical brain tissue, CTX0E03 is a clonal
cell line that contains a single copy of the c-mycERTAM transgene delivered by retroviral infection.
Under the conditional regulation by 4-hydroxytamoxifen (4-OHT), c-mycERTAM enabled large-scale
stable banking of the CTX0E03 cells. In this study, we investigated the fate of this transgene
following growth arrest (EGF, bFGF and 4-OHT withdrawal) in vitro and following intracerebral
implantation into a mid-cerebral artery occluded (MCAo) rat brain. In vitro, 4-weeks after removing
growth factors and 4-OHT from the culture medium, c-mycERTAM transgene transcription is
reduced by ~75%. Furthermore, immunocytochemistry and western blotting demonstrated a
concurrent decrease in the c-MycERTAM protein. To examine the transcription of the transgene in
vivo, CTX0E03 cells (450,000) were implanted 4-weeks post MCAo lesion and analysed for human
cell survival and c-mycERTAM transcription by qPCR and qRT-PCR, respectively.
Results: The results show that CTX0E03 cells were present in all grafted animal brains ranging
from 6.3% to 39.8% of the total cells injected. Prior to implantation, the CTX0E03 cell suspension
contained 215.7 (SEM = 13.2) copies of the c-mycERTAM transcript per cell. After implantation the
c-mycERTAM transcript copy number per CTX0E03 cell had reduced to 6.9 (SEM = 3.4) at 1-week
and 7.7 (SEM = 2.5) at 4-weeks. Bisulfite genomic DNA sequencing of the in vivo samples confirmed
c-mycERTAM silencing occurred through methylation of the transgene promoter sequence.
Conclusion: In conclusion the results confirm that CTX0E03 cells downregulated c-mycERTAM
transgene expression both in vitro following EGF, bFGF and 4-OHT withdrawal and in vivo following
implantation in MCAo rat brain. The silencing of the c-mycERTAM transgene in vivo provides an
additional safety feature of CTX0E03 cells for potential clinical application.
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Background
Stem cell therapy is a facet of regenerative medicine that
aims to ameliorate the damage caused to the brain by the
grafting of healthy "reparative" cells. Pioneering studies
implanting mouse neural stem cells (NSCs) into the
brains of stroke animals have demonstrated significant
recovery in motor and cognitive tests [1-5]. These findings
provide a rational approach to the development of a cell
based therapy for ischemic stroke. A substantial and con-
sistent supply of allogeneic NSCs is required in order to
treat a large patient population. Unfortunately, human
NSCs are somatic stem cells and susceptible to genetic and
phenotypic changes and loss of biological activity follow-
ing extensive tissue culture expansion [6-8].
Immortalization of NSCs overcomes their restricted
expansion potential. The myc proto-oncogene has proven
a successful tool for immortalization of NSCs [9-16]. In
these research applications, both v- and c-myc promote
consistent and enhanced tissue culture expansion of
human NSCs while maintaining a stable karyotype and
retaining biological activity. The c-mycERTAM technology
has proven to be as successful in generating immortalized
neural stem cell lines as c-myc alone [17-20]. The c-myc-
ERTAM transgene is better suited as an immortalizing agent
for clinical applications because c-Myc protein function is
conditional on the presence of the tamoxifen metabolite,
4-hydroxytamoxifen (4-OHT). The translated c-MycERTAM
recombinant protein is a conjugation of human c-Myc
and modified mouse estradiol receptor (ER) and is
present as an inactive monomer in the cytosol of the cell.
When added to the tissue culture medium, 4-OHT specif-
ically binds to the ER moiety causing the c-MycERTAM pro-
tein to dimerize and subsequently translocate to the cell
nucleus where c-Myc is active as a transcription factor
[21].
CTX0E03 is a human NSC line that was derived using c-
mycERTAM technology and showed recovery in sensorimo-
tor deficits following grafting in MCAo rodent brain
[19,22]. One copy of the c-mycERTAM transgene is inte-
grated into the CTX0E03 cell genome (chromosome 13)
under the cytomegalovirus (CMV) immediate early pro-
moter [19]. We have shown that the c-mycERTAM trans-
gene is expressed in proliferating CTX0E03 cell cultures in
vitro; however, the expression of this transgene following
the grafting of CTX0E03 cells in vivo was not characterized.
Although neoplasm formation has never been observed
with CTX0E03 cells in multiple pre-clinical studies, this
information would nonetheless be important in assessing
the inherent risk of using a genetically modified cell line
for clinical applications.
Analysis of transgene expression following implantation
of genetically modified cells is challenging because of the
relatively small proportion of implanted cells compared
to the host. Using a fluorescent reporter transgene, the
CMV promoter has been shown to undergo silencing in
grafted hematopoietic cells in vivo [23]. In another exam-
ple, Lee et al. demonstrated by immunohistochemistry
(IHC) that v-myc was silenced following intracerebral
implantation of immortalized HBF1.3 cells [24]. Unfortu-
nately, these methodologies were not appropriate for our
application. The c-mycERTAM transgene in CTX0E03 cells
does not contain a fluorescent reporter that could be
monitored. With respect to IHC, we were concerned it
would be inconclusive due to the unknown sensitivity
and potential cross-reactivity of the antibodies. Further-
more, IHC was ruled out since the analysis would be lim-
ited to a finite number of sections and would not
encompass all cells present in the graft.
In this study, we developed a novel and sensitive method
that is able to analyze absolute gene expression within
human genetically modified cells grafted into rodent
brain. This method used the human specific Alu genomic
sequence to detect and quantify CTX0E03 cells grafted
within the rodent brain background [25,26]. Absolute
quantification of c-mycERTAM transcription made it possi-
ble to calculate the number of c-mycERTAM transcript cop-
ies per CTX0E03 cell. Using this methodology, c-
mycERTAM transgene silencing was shown following graft-
ing of CTX0E03 cells into MCAo rat brain. Although not
intentionally incorporated into the design technology of
c-mycERTAM, silencing of the CMV transgene promoter in
vivo demonstrates an additional safety feature of this tech-
nology and of the CTX0E03 cells.
Results
Alu and c-mycERTAM assay design
The analysis of the c-mycERTAM transcript expression per
CTX0E03 cell, both in vivo and in vitro, was dependent
upon the ability to sequentially purify genomic DNA
(gDNA) and RNA from the same biological sample using
the All DNA/RNA Kit (Qiagen). The gDNA preparation
yielded one single band by agarose gel electrophoresis
with no evidence of degradation or contaminating RNA
(Figure 1A). The RNA preparation yielded the expected
28S and 18S bands, again with no degradation or DNA
contamination visible (Figure 1B). Standard curves were
then generated to determine: 1) the number of CTX0E03
cells present in a gDNA sample by Alu qPCR (Figure 1C);
and 2) the number of c-mycERTAM transcripts present in a
retro-transcribed RNA reaction sample (Figure 1D). The
Alu sequence assay could reproducibly detect human
CTX0E03 gDNA with as few as one CTX0E03 cell per reac-
tion; whereas, the c-mycERTAM assay could detect as few as
10 copies per reaction.BMC Neuroscience 2009, 10:86 http://www.biomedcentral.com/1471-2202/10/86
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Alu sequence and c-mycERTAM assay development and validation Figure 1
Alu sequence and c-mycERTAM assay development and validation. Gels showing the quality and purity of gDNA by 
agarose gel electrophoresis (A) and RNA by virtual gel produced by Agilent 2100 Bioanalyzer (B, RNA Integrity Number >9.4 
as analyzed by Agilent RNA 600 nano kit [32]) isolated from the same sample. Standard curves used to determine: cell number 
by Alu sequence qPCR (C, Error 0.0300, efficiency 1.993; 3 replicates); absolute c-mycERTAM copy number by c-mycERTAM qRT-
PCR (D, Error 0.0837 and efficiency 2.131; 3 replicates). All standard curves were generated from CTX0E03 gDNA diluted in 
rat gDNA or cDNA. Crossing point refers to the number of PCR cycles required to generate a detectable fluorescent signal 
generated on a Roche LC480 instrument. Positive control rat brain samples (B1 and B2) were grafted with approximately 
300,000 CTX0E03 cells each and harvested immediately (E, F). Data shown is the total number of CTX0E03 cells in each tissue 
section as determined by Alu, where control is the number of viable cells in the cell suspension prior to injection as deter-
mined by counting using a haemocytometer (E); and total c-mycERTAM transcript copy number calculated per CTX0E03 cell 
detected in brain samples, where control is the number of copies per cell detected in vitro culture (F).BMC Neuroscience 2009, 10:86 http://www.biomedcentral.com/1471-2202/10/86
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Validation of Alu and c-mycERTAM assays
The Alu sequence and c-mycERTAM transcription assays
were developed in the presence of rat brain gDNA or
cDNA, as described in the Methods. These experiments
involved mixing purified CTX0E03 DNA/cDNA with puri-
fied rat brain DNA/cDNA. However, in order to verify that
CTX0E03 cells grafted in rat brain could be processed and
analysed effectively together a positive control experiment
was carried out. This experiment consisted of harvesting
and processing the rat brain tissue immediately after a 6 μl
injection of CTX0E03 cells was delivered. It was deter-
mined by counting using a haemocytometer that the cell
suspension prior to delivery contained 46,600 cells/μl –
i.e. total of 279,600 cells were present in 6 μl loaded into
the syringe. By Alu sequence analysis, the injected rat
brain tissue sections contained an average of 241,116
(SEM = 15,487) CTX0E03 cells (Figure 1F). The measured
number of CTX0E03 cells is within the range expected.
Analysis of the total RNA isolated from these samples
showed CTX0E03 cells to express on average 236.9 (SEM
= 7.8) c-mycERTAM transcript copies per cell (Figure 1G).
Control CTX0E03 cells measured in culture were shown to
have a similar value of 242.3 (SEM = 47.8) c-mycERTAM
transcript copies per cell.
CTX0E03 cell detection and quantification in vivo
Four weeks after the MCAo, a total of 450,000 CTX0E03
cells were implanted bilaterally into the putamen. The rats
were sacrificed 1-week or 4-weeks post-implantation,
their brains were removed and sections encompassing the
injection tracts were dissected and snap frozen in liquid
nitrogen. The Alu and c-mycERTAM assays were then car-
ried out on the gDNA and cDNA isolated from each tissue
section, respectively. CTX0E03 cells were detected in all
implanted animals at both time points, with a range of
28,151 to 179,184 CTX0E03 cells detected per brain. The
total number of CTX0E03 cells detected, per rat brain, is
shown at 1-week (Figure 2A) and 4-weeks (Figure 2B)
post-implantation. An aliquot of the CTX0E03 cell sus-
pension prepared for implantation was retained and used
to determine the pre-implantation c-mycERTAM transcript
copy number. The average c-mycERTAM transcription level
for the three CTX0E03 cell suspensions prepared in this
study was found to be 215.7 (SEM = 13.2) copies per cell
(Figure 2C). This is compared to the population of
CTX0E03 cells detected in vivo, where the average number
of c-mycERTAM transcript copies per CTX0E03 cell was cal-
culated to be 6.9 (SEM = 3.4) at 1-week and 7.7 (SEM =
2.5) at 4-weeks (Figure 2C). The number of CTX0E03
cells, the number c-mycERTAM transcripts calculated per
tissue section and the resultant number of c-mycERTAM
transcript copies per CTX0E03 cell, are shown in Table 1.
c-MycERTAM  transcripts were detected within approxi-
mately 50% of the tissue sections containing CTX0E03
cells at both time points. It is important to note, in no
instance was a c-mycERTAM  transcript signal detected
where CTX0E03 cells were absent.
Transgene methylation analysis
Direct modification of the DNA by methylation is an epi-
genetic mechanism to downregulate or silence gene
expression. Using bisulfite sequencing, the methylation
status of the CMV transgene promoter was investigated in
CTX0E03 cells pre- and post-implantation. The CMV pro-
moter of the transgene contains numerous potential
methylation sites within a CpG rich island (Figure 3A).
Bisulfite sequencing of gDNA clones taken from control
non-implanted CTX0E03 cells showed only 2% of these
CpG sites were methylated (Figure 3B). However, the
same analysis carried out on clones obtained from the
CTX0E03 cell implanted MCAo rat brain samples showed
that 86.8% (SEM = 7.1) and 75.0% (SEM = 1.4) of the
CpG islands were methylated at 1-week and 4-weeks,
respectively (Figure 3B). There was no statistical difference
between 1- and 4-weeks, p = 0.14, indicating that the
methylation had occurred within the first week and was
constant to the 4-week time point. Collectively, only four
gDNA transgene promoter clones in vivo were found to be
devoid of any methylated sites from a total of 99 analysed;
in other words, ~96% of the transgene promoter
sequences analysed in vivo where found to contain at least
one methylated CpG island.
In vitro characterization
Additional experiments were carried out in vitro to deter-
mine if a reduction in transgene transcription leads to a
concomitant reduction in translated protein. Analyses
were carried out on control CTX0E03 cells and those cul-
tured for 1- and 4-weeks in the absence of growth factors
and 4-OHT. In this non growth permissive condition,
transgene transcription was found to decrease by 59.6% at
1-week and 73.4% at 4-weeks relative to control by qRT-
PCR (Figure 4A). Analysis of c-MycERTAM protein was per-
formed by colocalization of c-Myc and ERα antigen stain-
ing by immunocytochemistry (ICC; Figure 4B, C, D, E).
The c-Myc and ERα antigens were always found to colocal-
ize in the nucleus of a proportion of CTX0E03 cells, indi-
cating that the antibodies were detecting the c-MycERTAM
target (Figure 4E). Immunoreactive cells were counted
and expressed as a proportion of total cells. These data
showed control CTX0E03 cell cultures were approxi-
mately 52.0% positive for c-MycERTAM; whereas, follow-
ing EGF, bFGF and 4-OHT withdrawal the number of
CTX0E03 cells positive for c-MycERTAM were 42.5% at 1-
week and 12.8% at 4-weeks (Figure 4B). Western blot
analysis using the c-Myc and ERα antibodies demon-
strated that total c-MycERTAM protein levels followed more
closely the progressive drop observed by gene expression
and were reduced by 53.8% at 1-week and 73.0% at 4-BMC Neuroscience 2009, 10:86 http://www.biomedcentral.com/1471-2202/10/86
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weeks following EGF, bFGF, and 4-OHT withdrawal (Fig-
ure 4F, G).
Discussion
The c-mycERTAM immortalization technology has been
successfully utilized to derive a clonal human neural stem
cell line from fetal cortical brain. This cell line, referred to
as CTX0E03, possess biological attributes which are desir-
able for clinical applications for stroke therapy. Namely,
this cell line can be continuously expanded in vitro, and
following implantation in MCAo rodent brain, results in
sensorimotor recovery in the absence of cell treatment-
related histopathology [19,22]. The in vitro effects of c-
mycERTAM in the CTX0E03 cell line have been well charac-
terized. Here we investigated the expression of this trans-
gene following implantation of CTX0E03 cells into MCAo
rat brain.
In this paper we report a novel method to examine abso-
lute gene expression within human cells implanted into
rodent brain. In this example, we analyzed the number of
c-mycERTAM transcript copies per CTX0E03 cell both in
vitro  and in vivo. The calculated c-mycERTAM copies per
CTX0E03 cell prepared directly from fresh culture (242.3;
SEM = 47.8), cell suspension prior to implantation
(215.7; SEM = 13.2) or immediately following implanta-
tion (236.9; SEM = 7.8) had comparable values. This val-
idated that the assays employed were CTX0E03 cell
specific and the rodent brain background did not cause
any interference. Using these established assays, c-mycER-
TAM transgene transcription was analyzed in the surviving
Detection of CTX0E03 cells and c-mycERTAM transcription in grafted rat brain Figure 2
Detection of CTX0E03 cells and c-mycERTAM transcription in grafted rat brain. Total cells found at 1-week (A) and 
4-weeks (B) post-implantation by Alu qPCR. Animal numbers 103, 304, 401, 402 and 603 were vehicle injected only control 
brain samples. Absolute quantification of c-mycERTAM transcript level per CTX0E03 cell, in cell suspensions prior to implanta-
tion (control) and in vivo (C).B
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Table 1: c-MycERTAM transcript copy number and number of CTX0E03 cells calculated in the grafted rat brain sections at 1- and 4-weeks post-implantation
Week 1 Week 4
Rat# region Total c-
mycERTAM
copy #
Total cell #
Alu assay
Total c
-mycERTAM 
copy #/Total cell
# Alu assay
c-mycERTAM
copy # per cell
per animal
Rat# region Total c
-mycERTAM
copy #
Total cell
# Alu assay
Total c
-mycERTAM 
copy #/Total cell
# Alu assay
c-mycERTAM 
copy # per cell
per animal
201 F1 N.D.1 N.D.2 N/A 203 F1 N.D. N.D. N/A
201 F2 N.D. 1066.9 0.0 203 F2 N.D. N.D. N/A
201 FN1 18671.8 18821.5 1.0 203 FN1 N.D. 1776.9 0.0
201 FN2 N.D. 11695.4 0.0 0.8 203 FN2 N.D. 15046.2 0.0
301 F1 N.D. 530.8 0.0 203 C 521495.6 68123.1 7.7 6.1
301 F2 N.D. 356.8 0.0 204 F1 902695.4 45261.5 20.0
301 FN1 N.D. 16269.2 0.0 204 F2 N.D. 5563.1 0.0
301 FN2 N.D. 10993.9 0.0 0.0 204 FN1 N.D. 4850.8 0.0
302 F1 N.D. 1075.4 0.0 204 FN2 418067.7 45661.5 9.2 13.0
302 F2 N.D. 837.7 0.0 403 F1 N.D. N.D. N/A
302 FN1 909865.9 42992.3 21.1 403 F2 264100.0 5501.5 48.0
302 FN2 N.D. 18664.6 0.0 14.3 403 FN1 388332.3 85000.0 4.6
501 F1 N.D. N.D. N/A 403 FN2 224224.0 17169.2 13.1
501 F2 550.1 17846.2 0.0 403 C 1324893.5 47584.6 27.8 14.2B
M
C
 
N
e
u
r
o
s
c
i
e
n
c
e
 
2
0
0
9
,
 
1
0
:
8
6
h
t
t
p
:
/
/
w
w
w
.
b
i
o
m
e
d
c
e
n
t
r
a
l
.
c
o
m
/
1
4
7
1
-
2
2
0
2
/
1
0
/
8
6
P
a
g
e
 
7
 
o
f
 
1
3
(
p
a
g
e
 
n
u
m
b
e
r
 
n
o
t
 
f
o
r
 
c
i
t
a
t
i
o
n
 
p
u
r
p
o
s
e
s
)
501 C1 2858994. 9 123000.0 23.2 404 F1 N.D. 2738.5 0.0
501 C2 N.D. 2701.5 0.0 19.9 404 F2 31223.6 11076.9 2.8
601 F1 N.D. N.D. N/A 404 FN1 N.D. 146750.0 0.0
601 F2 N.D. 964.2 0.0 404 FN2 218605.5 15061.5 14.5
601 FN1 10151.6 70061.5 0.9 404 F ANT N.D. 3556.9 0.0 0.4
601 FN2 109810.0 18692.3 5.9 1.3 502 F1 N.D. 241.4 0.0
602 F1 380824.6 41123.1 9.3 502 F2 N.D. 1046.2 0.0
602 F2 N.D. 24076.9 0.0 502 FN1 150198.4 12776.9 11.7
602 C 40085.1 11253.9 3.6 502 FN2 224974.8 19261.5 11.7 11.3
602 FL N.D. 6541.5 0.0 5.1 503 F1 N.D. N.D. N/A
503 F2 N.D. N.D. N/A
503 FN1 N.D. 1230.8 0.0
503 FN2 N.D. 13292.3 0.0
503 C N.D. 19692.3 0.0
Mean 6.9 Mean 7.7
SEM 3.4 SEM 2.5
1N.D. Not Detected, signal was below the level of 10 c-mycERTAM copies per reaction
2N.D. Not Detected, signal was below the level of one CTX0E03 cell per reaction
Table 1: c-MycERTAM transcript copy number and number of CTX0E03 cells calculated in the grafted rat brain sections at 1- and 4-weeks post-implantation (Continued)BMC Neuroscience 2009, 10:86 http://www.biomedcentral.com/1471-2202/10/86
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CTX0E03 cell population at 1- and 4-weeks post-implan-
tation in MCAo rodent brain. At both time points there
was a substantial reduction in the calculated number of c-
mycERTAM transcript copies per CTX0E03 cell detected.
This molecular biological approach provided many
advantages over immunohistochemistry and in situ
hybridization techniques. The results obtained by RT-PCR
and PCR were quantitative. Immunohistochemistry or in
situ hybridization techniques do not permit the quantita-
tive assessment of c-mycERTAM levels within a given cell. In
addition, the sensitivity of molecular biological tech-
niques were defined, as a single CTX0E03 cell and ten cop-
ies of c-mycERTAM per reaction, respectively; whereas, this
level of sensitivity would have been difficult, if not impos-
sible, to achieve by immunohistochemistry or in situ
hybridization techniques. Our in vivo samples were proc-
essed rapidly, immediately after harvesting, thus captur-
ing the most accurate data. Furthermore, from a practical
perspective this molecular biological approach analyzed
all CTX0E03 cells present in the rodent brain, whereas,
histological preparation methods would require a large
number of sections to analyze all cells present. Although
the average transgene expression significantly decreased in
vivo, we cannot exclude the possibility that the expression
observed may have arisen from a limited number of
CTX0E03 cells. However, the silencing of c-mycERTAM
expression observed in vivo is consistent with the absence
of tumor formation derived from CTX0E03 cells when
implanted in vivo [19,22].
Transgene silencing can occur at a transcriptional or post-
transcriptional level. Long-term transcriptional silencing
of retrovirus-delivered genes has been shown largely to
result from methylation of the cytosine nucleotides
within the promoter regions [27]. The factors responsible
In vivo analysis of CpG methylation within the c-mycERTAM promoter region in CTX0E03 cells Figure 3
In vivo analysis of CpG methylation within the c-mycERTAM promoter region in CTX0E03 cells. CpG dinucle-
otide-containing regions (underlined) examined in CMV promoter of the c-mycERTAM transgene (A). Methylation sequence 
analysis of the CMV transgene promoter region of in vivo and in vitro samples (B). Ten animal grafted brains were analyzed, five 
at 1-week (top set) and five at 4-weeks (bottom set), in addition, a non-implanted CTX0E03 cell sample (control). Ten clones 
containing the sequence depicted in (A) from each grafted rat brain were analyzed. Each row shown represents a clone. Filled 
circles = methylated CpG island; open circles = unmethylated CpG island. Percentages of global methylation are reported at 
the bottom of each sample.BMC Neuroscience 2009, 10:86 http://www.biomedcentral.com/1471-2202/10/86
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In vitro characterisation of c-mycERTAM transcript and protein expression Figure 4
In vitro characterisation of c-mycERTAM transcript and protein expression. CTX0E03 cells were cultured in growth 
medium (control) and in non-growth promoting medium (in the absence of growth factors and 4-OHT) for 1- and 4-weeks. 
Evaluation of c-mycERTAM gene transcript and protein levels were performed by qRT-PCR (A), ICC (B to E) and western blot 
(F). CTX0E03 cell ICC images shown in panels C to E are representative images of the control c-Myc (green), ERα (red) and 
overlay (Merge). Scale bars represent 50 μm. The western blots in panel F were quantified using densitometry normalised by 
α-tubulin (G).BMC Neuroscience 2009, 10:86 http://www.biomedcentral.com/1471-2202/10/86
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for DNA methylation is reviewed in detail elsewhere [28].
As the c-mycERTAM  transgene was delivered into the
CTX0E03 cell line using a retrovirus, it was reasonable to
speculate that transgene silencing had occurred through
methylation of CpG islands within the transgene pro-
moter region. Bisulfite DNA sequencing was used to deter-
mine the methylation status of the CMV promoter region
of the c-mycERTAM transgene within CTX0E03 cells. In cul-
ture, only 6 of the total CpG sites screened were found to
be methylated. In the samples prepared from CTX0E03
grafted MCAo rodent brain 62 to 100% of the sites were
methylated. These data unequivocally show that c-mycER-
TAM expression is silenced at a transcriptional level in vivo
as a result of DNA methylation within the CMV transgene
promoter region.
The c-mycERTAM technology acts at a protein rather than a
transgene expression level. To mitigate the risk of the tech-
nology following intracerebral implantation of CTX0E03
cells it was important to investigate if c-mycERTAM tran-
scription level was a predictive measure of the recom-
binant protein level. Western blot analysis of the in vivo
samples proved impossible because the c-MycERTAM pro-
tein would be too dilute to detect in whole brain extracts.
In addition, IHC analysis of the in vivo samples was
impractical because of the substantial number of sections
required to perform a global analysis of c-MycERTAM pro-
tein expression. To overcome these challenges we devel-
oped and in vitro model of c-mycERTAM  silencing in
CTX0E03 cells. The kinetics of transgene silencing in vitro
was slower than that observed in vivo, which provided the
ideal cell culture model to directly compare the progres-
sive decline in c-mycERTAM transcription with the trans-
lated protein level. Although we observed a decrease in
the number of c-mycERTAM positive cells by ICC, the rela-
tive percentage of positive cells did not closely follow rel-
ative transgene expression levels. These ICC findings
further highlight the drawback of histological approaches
because the cells were scored positive independent of the
quantity of c-MycERTAM protein present within the cell.
On the other hand, when total c-MycERTAM protein levels
were measured by western blot they were found to
decrease in parallel with transgene transcript level over the
1- to 4-week period. This data indicates that the c-mycER-
TAM transcript and protein levels are closely linked in
CTX0E03 cells.
Conclusion
In conclusion, we have demonstrated that c-mycERTAM
transgene expression levels in CTX0E03 cells were signifi-
cantly reduced in vitro, upon growth factor and 4-OHT
withdrawal, and in vivo following implantation. We dem-
onstrated that in vivo transgene silencing occurred through
DNA methylation. In addition, the in vitro results showed
that c-mycERTAM transcription level was representative of
the c-MycERTAM protein level. The data demonstrate that
uncontrolled in vivo cell growth arising from c-mycERTAM
technology is unlikely based on both the silencing of the
c-mycERTAM gene expression reported here and the specific
requirement for the 4-OHT ligand to activate the c-MycER-
TAM protein. Furthermore, these data demonstrate that the
retroviral insertion of stable transgene constructs into
human neural stem cells with the CMV promoter element
is not an inherently unsafe procedure for the production
of cellular therapies.
Methods
Ethics statement
Fetal tissue used to derive CTX0E03 cells was obtained in
accordance with nationally (UK and/or USA) approved
ethical and legal guidelines. All animal work was per-
formed in accordance with the UK Animals (Scientific
Procedures) Act (1986) and approved by the local animal
Ethical Review Committee.
Derivation of CTX0E03
The CTX0E03 clonal cell line was derived from human
fetal brain cortical tissue of 12 weeks' gestation, as
described previously [19]. Briefly, a mixed culture was ini-
tiated from the dissociated cortex tissue and was infected
with an amphotropic replication-incompetent retroviral
vector (pLNCX-2; Clontech) encoding the c-mycERTAM
transgene. The CTX0E03 clonal cell line was isolated using
a ring cloning method. The CTX0E03 cells were routinely
cultured as a monolayer on mouse laminin (Trevigen,
AMS Biotechnology, UK) freshly coated flasks in serum
free medium (RMM) containing the growth factor supple-
ments 10 ng/ml bFGF (Peprotech), 20 ng/ml EGF (Pepro-
tech), and 100 nM 4-OHT (Sigma). All experiments were
carried out using CTX0E03 cells between passage number
33 to 37, which corresponds to a population doubling
level (PDL) ranging between 65 to 75.
MCAo and cell grafting
Male Sprague-Dawley rats (Charles River) were group
housed with food and water ad libitum. Briefly, animals
were subjected to 60 minutes of unilateral MCAo initiated
under halothane anesthesia [29]. At 50 minutes into the
occlusion, animals were evaluated for behavioral dysfunc-
tion (forelimb flexion and contralateral circling behav-
ior). Animals that did not demonstrate dysfunction were
removed from the study.
CTX0E03 cells were harvested and suspended at a concen-
tration of ~50,000 cells/μl in HBSS-NAC (HBSS without
calcium, magnesium and containing 0.5 mM N-acetyl
cysteine; Sigma) and implanted 4-weeks ± 3 days after the
occlusion. Each grafted animal received two 4.5 μl bolus
injections (approximately 225,000 cells/site with control
lesioned animals receiving vehicle only) over 68 sec withBMC Neuroscience 2009, 10:86 http://www.biomedcentral.com/1471-2202/10/86
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4 min rest before withdrawal. Coordinates from bregma
were as follows: Site 1) AP 0.0 mm, L -3.6 mm, V -5.5 mm
(from skull surface at bregma); and Site 2) AP 0.0 mm, L
+3.6 mm, V -5.5 mm (from skull surface at bregma). Ani-
mal brains were collected at 1-week (6 grafted + 2 non-
grafted controls) or 4-weeks (6 grafted + 3 non-grafted
controls) post-implantation. All animals were adminis-
tered Cyclosporin A (20 mg/kg, Sandoz Pharmaceuticals)
in cremaphore L (Sigma) a day prior to grafting, the day of
grafting and then three times weekly for the remaining
duration of the study. In addition, Methylprednisolone
(Pharmacia Upjohn) was administered at 20 mg/kg for
the first 14 days, 10 mg/kg for days 15–17 and 5 mg/kg for
days 18–19 post-grafting.
Alu sequence assay to detect and quantify CTX0E03 cells
The qPCR Alu assay was carried out using the LightCycler
480 and the Probes Master mix (Roche). Briefly, an aver-
age of 250 ng of genomic DNA was amplified using spe-
cific primers (Forward-TGAGGCAGGCGAATCGCTTGAA,
Reverse-GACGGAGTTTCGCTCTTGTTG) and a FAM-
labeled fluorogenic probe (CGCGATCTCGGCTCACT-
GCAACCTCCATCG) (PrimerDesign) against a conserved
region of the human Alu-Sq sequence (Accession number
U14573). The PCR was preformed under the following
conditions: 95°C for 30 seconds, followed by 45 cycles of
95°C for 15 s, 58°C for 30 s, 72°C for 15 s. Quantifica-
tion of the human CTX0E03 DNA in rat tissue was based
on a standard curve using serial dilutions that ranged from
1 to 10000 CTX0E03 cells, calculated on the assumption
that one human cell contains 6.6 pg of gDNA [30]. The
standard curve was performed in the presence of 250 ng of
rat gDNA.
CTX0E03 c-mycERTAM transgene transcription assay
Primers were designed to specifically detect the relative c-
mycERTAM transgene transcription level in CTX0E03 cells
using the Roche Diagnostics Lightcycler LC480 system.
Using SYBR Green Master mix (Roche) and primers (For-
ward-AAAGGCCCCCAAGGTAGTTA, Reverse- AAG-
GACAAGGCAGGGCTATT), which amplified the c-myc
and estrogen receptor (ER) junction, qPCR was performed
under the following conditions: 95°C for 5 s, followed by
45 cycles at 95°C for 10 s, 60°C for 20 s,72°C for 20 s,
82°C for 5 s, measuring the fluorescence. A melt curve
analysis was also performed after the assay to check the
specificity of the reaction using the following conditions:
95°C for 5 s, 65°C for 60 s (1°C increments) followed by
97°C continuous. In order to carry out absolute quantifi-
cation of c-mycERTAM transcription, a known concentra-
tion standard was required to plot a standard curve. Based
on the assumption that CTX0E03 cell contains one
genomic copy of the c-mycERTAM transgene [19] serial
dilutions ranging from 10 to 10,000 copies of c-mycERTAM
were used per reaction to produce the standard curve. The
standard curve was performed in the presence of rat
cDNA.
Calculation of c-mycERTAM transcription level in vivo
At 1- or 4-weeks post-implantation, the rat brains were
removed, cut into 50–250 mg sections and snap frozen in
liquid nitrogen. The gDNA and total RNA was then
sequentially isolated from each tissue piece using the All-
Prep DNA/RNA mini kit (Qiagen). Four tissue sections
were processed per rat brain (i.e. two tissue sections
encompassing each injection tract). In brief, the tissue
samples were homogenised in the supplied lysis buffer
according to sample weight. The lysed sample was proc-
essed first through an AllPrep DNA spin column, to iso-
late the gDNA, and subsequently through an RNeasy spin
column to selectively isolate RNA. The gDNA and total
RNA samples (1 μl/reaction) were then analyzed by qPCR
for Alu signal and qRT-PCR for c-mycERTAM, respectively.
Based on the Alu signal, the number of CTX0E03 cells
present per reaction was calculated from the standard
curve. Similarly, the number of c-mycERTAM transcripts
present per reaction was interpolated from the c-mycER-
TAM copy number standard curve. A calculation was then
carried out to correct for the amount analyzed and the
total volume of tissue sample lysate (for example, 1 μl
from a total of 650 μl). The corrected figures were then
expressed as the number of c-mycERTAM transcripts present
over the number of CTX0E03 cells present in each tissue
section. Standard error of the mean was calculated for all
tissue sections found to contain cells (Microsoft Excel ver-
sion 2003).
Transgene methylation analysis by bisulfite sequencing
Bisulfite treatment of DNA followed by sequencing was
used to determine the endogenous transgene promoter
pattern of methylation in CTX0E03 cells. Methylation is
implicated in repression of genetic activity and involves
the addition of a methyl group to the carbon-5 position of
cytosine residues of the dinucleotide CpG. Bisulfite
sequencing is a technique used to identify specific gDNA
methylation sites based on the fact that treatment of DNA
with bisulfite converts cytosine residues to thymidine, but
leaves 5-methylcytosine residues unaffected. Bisulfite
treatment thus introduces a specific change in the DNA
sequence which is dependent on the methylation status of
individual cytosine residues. A bisulfite reaction was per-
formed using Epitect Bisulfite (Qiagen). Up to 2 μg of
genomic DNA was used for conversion with the bisulfite
reagent. Bisulfite-converted DNA was used as a template
for PCR amplification. PCR primers were designed using
the web program METHPRIMER ([31]; http://www.uro
gene.org/methprimer/index1.html). Primers used were:
Forward – GGGAGTTTGTTTTGGTATTAAAATTAA and
Reverse – ACTACTACTAATAAAAATTCTCCTCCTC. PCR
conditions were 94°C for 5 minutes, 30 cycles of 94°C forBMC Neuroscience 2009, 10:86 http://www.biomedcentral.com/1471-2202/10/86
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30 seconds, 60°C for 1 min, and 72°C for 30 seconds fol-
lowed by 10 min at 72°C. PCR fragments were cloned
into TA-cloning vector using TOPO TA Cloning Kit for
Sequencing (Invitrogen). Ten individual clones were
sequenced by GATC Biotech (Germany) using the T3 uni-
versal PCR primers. The resulting sequences were ana-
lyzed using blast software http://blast.ncbi.nlm.nih.gov/
Blast.cgi. Sequence analysis that identified an unchanged
cytosine base (i.e. protected from the bisulfite conversion
reaction) was considered to be methylated, but a cytosine
conversion to thymidine in the sequence indicated no
methylation.
In vitro characterisation: western blot and 
immunocytochemical analysis
In vitro, CTX0E03 cell samples were prepared by maintain-
ing the cells in non-growth permitting medium alone,
without the addition of EGF, bFGF, and 4-OHT, for 1- and
4-weeks. Western blot analysis for c-mycERTAM protein in
CTX0E03 cells was carried out using the whole-cell lysate.
To prepare cell lysate, CTX0E03 cell monolayers in a T75
flask were rinsed with cold PBS (4°C), lysed with 750 μl
1× SDS Sample Buffer and dithiothreitol (DTT) Reducing
Agent (PAGEgel Inc, AMS Biotechnology, UK), and col-
lected in a 1.5 ml centrifuge tube. Samples were triturated
multiple times to lyse and shear the sample, heated at
100°C for 2 min and centrifuged. Cell lysates were loaded
onto a 4%–20% Tris-Tricine gel (PAGEgel Inc, AMS Bio-
technology, UK), 10 μl per well. After electrophoresis, the
protein was transferred onto a nitrocellulose membrane
with 0.2 μm pore size by electroelution. Immunodetec-
tion was performed with a rabbit anti-ERα polyclonal or a
mouse anti-c-Myc monoclonal antibody (Santa Cruz Bio-
technology Inc, both used at 1:100). Transgene product
was detected using horseradish peroxidase-conjugated
anti rabbit-IgG (Cell Signaling Technology, 1:2000) or
anti mouse-IgG (Pierce Biotechnology Inc., 1:800) sec-
ondary antibodies, as appropriate. The nitrocellulose
membrane was then processed using chemiluminescence
detection reagents (Thermo scientific). The blots were
then stripped and reprobed using anti-α-tubulin (Sigma,
1:1000) to act as an internal loading level standard. West-
ern blot images were captured using BioRad FluorS Imag-
ing Unit and densitometry carried out using Scion Image
software (Scion Corporation, version Alpha 4.0.3.2,
USA).
Immunocytochemistry was carried out on CTX0E03 cells
fixed in a 96-well plate (BD) using 4% PFA/4% sucrose in
PBS for 15 min after 3 days growth (control) and follow-
ing 1- and 4-weeks in medium containing no growth fac-
tors (EGF, bFGF) or 4-OHT. Anti-c-myc (1:100) and anti-
ERα (1:500) were incubated in 1xPBS containing 1% nor-
mal goat serum (Vector laboratories) overnight at room
temperature. After rinsing, the CTX0E03 cells were incu-
bated for 1.5 h at room temperature using anti-mouse
conjugated Alexa Fluor 488 (Invitrogen, 1:2000) for c-
myc and anti-rabbit conjugated Alexa Fluor 568 (Invitro-
gen, 1:2500) for ERα. CTX0E03 cells were then counter-
stained by incubating with Hoechst 33342 (Sigma, 1 μM)
for 2 min. Quantification of c-myc and ERα was carried
out by manual counting of three representative fields
using an Olympus IX70 fluorescent microscope.
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